Skip to main content

Table 2 Gilliam Autism Rating Scale-2 (GARS-2) mean scores

From: Effect of intranasal oxytocin combination therapy with applied behavior analysis on social impairments in pediatric’s children with autism spectrum disorder

Variable

Time

INT-OXT

NS

Between groups

Follow-up time

Interaction (time × group)

Autism index

Baseline

76.9 ± 14.5

75.2 ± 8.7

p < 0.05

p < 0.001

p < 0.001

Treatment onset

68.4 ± 14.5

66.6 ± 13.4

Treatment ending

60.8 ± 12.1

71.2 ± 11.8

Ending follow-up

54.19 ± 15.13

69.78 ± 11.12

Stereotyped behaviors

Baseline

24.1 ± 5.5

25.7 ± 4.7

p < 0.05

p < 0.001

p > 0.05

Treatment onset

21.4 ± 5.7

22.4 ± 5.5

Treatment ending

19.1 ± 3.9

22.5 ± 4.2

Ending follow-up

16.6 ± 5.9

21.3 ± 4.6

Communication

Baseline

25.9 ± 5.1

24.7 ± 4.2

p > 0.05

p < 0.001

p < 0.001

Treatment onset

24.1 ± 5.8

23.4 ± 5.4

Treatment ending

21.6 ± 5.1

24.4 ± 4.6

Ending follow-up

18.3 ± 5.8

24.3 ± 4.1

Social interactions

Baseline

26.8 ± 6.1

24.8 ± 3.1

p > 0.05

p < 0.001

p < 0.001

Treatment onset

22.8 ± 5.3

20.7 ± 3.9

Treatment ending

20.2 ± 5

24.3 ± 4.9

Ending follow-up

19.3 ± 5.8

24.2 ± 4.6

  1. INT-OXT intranasal oxytocin, NS normal saline. Categorical data were compared using chi-square, and the repeated-measure ANOVA model was used for continuous parameters